Glycoprotein News and Research

RSS

T-cell immunity remains effective against SARS-CoV-2 Omicron subvariants

Omicron subvariants effectively escape B-cell immune responses by modifying neutralizing antibody epitopes.

21 Dec 2022

Trial of three vaccines for Zaire Ebola virus disease

Researchers perform two randomized controlled trials to determine immunogenicity and safety of three Ebola vaccines.

20 Dec 2022

Study identifies four new monoclonal antibodies with broad neutralizing potencies that target conserved SARS-CoV-2 epitopes

Researchers described four novel monoclonal antibodies with potent and broad neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the current globally dominant Omicron BA.4/BA.5.

20 Dec 2022

Safety and immunogenicity of the Omicron BA.4/BA.5-containing bivalent booster mRNA-1273.222

Researchers evaluated the immunogenicity and safety of the COVID-19 bivalent mRNA vaccine mRNA-1273.222 and tested the neutralizing ability of the two bivalent vaccines — mRNA-1273.222 and mRNA-1273.214 — against the newly emergent Omicron subvariants.

19 Dec 2022

Research reveals that a viral toxin may contribute to the severity of COVID-19

Researchers determine whether the SARS-CoV-2 spike protein influences endothelial and epithelial barrier dysfunction and vascular leakage.

14 Dec 2022

What is the relation between COVID-19 vaccination and new POTS-related diagnoses?

Researchers assessed the association between POTS and SARS-CoV-2 infections and COVID-19 vaccinations.

14 Dec 2022

The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

...

From The Native Antigen Company 8 Dec 2022

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Researchers reported the immunogenicity, efficacy, and safety of the MVA-BN (modified vaccinia Ankara-Bavarian Nordic)-RSV (respiratory syncytial virus) vaccine against RSV-A (RSV subtype A) Memphis 37b strain in a human challenge trial.

7 Dec 2022

Research extends the powerful tool of immunotherapy to autoimmune diseases

The cancer therapy known as CAR-T has revolutionized treatment of some blood cancers since it was introduced in 2017. The therapy uses genetically altered immune cells to home in on cancer cells and destroy them.

6 Dec 2022

The evolutionary trajectories and mechanisms driving the emergence of post-Omicron SARS-CoV-2 lineages

Researchers summarized the mechanisms through which the SARS-CoV-2 new Omicron sublineages are evolving.

30 Nov 2022

Could mRNA vaccines triumph over other viral infections in humans and domestic animals?

Researchers review potential areas for mRNA vaccine development against pathogenic viruses other than SARS-CoV-2.

28 Nov 2022

Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron

Isolated monoclonal antibodies neutralize SARS-CoV-2 Delta and Omicron variants.

28 Nov 2022

Feline coronavirus-infected domesticated cats found to possess cross-reactive anti-SARS-CoV-2 antibodies

In a recent study, researchers confirmed that feline coronavirus infection induced the production of cross-reactive antibodies against the SARS-CoV-2 receptor-binding domain in domestic cats.

28 Nov 2022

Pocket feature in SARS-CoV-2 spike protein is present in all deadly coronaviruses, study reveals

Scientists have discovered why some coronaviruses are more likely to cause severe disease, which has remained a mystery, until now.

24 Nov 2022

Ultrapotent IgM antibodies isolated from a pregnant woman with Zika virus show promise as an immunotherapy

Zika virus (ZIKV) infection is a potentially teratogenic illness, causing up to one in seven infants born to infected mothers to suffer neurodevelopmental deficits. A new study published in the journal Cell shows that some mothers escape injury to their babies because they develop a highly potent neutralizing antibody.

22 Nov 2022

Proteomic analysis identifies novel phenotypes associated with COVID-19 severity in circulating immune cells

In a recent study, researchers used proteomic analysis to identify novel immune cell phenotypes associated with severe coronavirus disease 2019 (COVID-19).

22 Nov 2022

Approved and developing passive and active immunizations against respiratory syncytial virus in childhood and pregnancy

Researchers explored active and passive vaccination among children against respiratory syncytial virus (RSV).

22 Nov 2022

The biological properties of the SARS-CoV-2 E protein in the context of HIV-1

Researchers assessed the effectiveness of SARS-CoV and SARS-CoV-2 envelope proteins against HIV-1.

22 Nov 2022

Kiwira virus: a new bat-borne hantavirus detected in Africa

Researchers discover a novel hantavirus called the Kiwira virus.

21 Nov 2022

NIAID awards more than $12 million for the development of antiviral therapies

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.

21 Nov 2022

Glycoprotein News and Research

T-cell immunity remains effective against SARS-CoV-2 Omicron subvariants

Trial of three vaccines for Zaire Ebola virus disease

Study identifies four new monoclonal antibodies with broad neutralizing potencies that target conserved SARS-CoV-2 epitopes

Safety and immunogenicity of the Omicron BA.4/BA.5-containing bivalent booster mRNA-1273.222

Research reveals that a viral toxin may contribute to the severity of COVID-19

What is the relation between COVID-19 vaccination and new POTS-related diagnoses?

The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Research extends the powerful tool of immunotherapy to autoimmune diseases

The evolutionary trajectories and mechanisms driving the emergence of post-Omicron SARS-CoV-2 lineages

Could mRNA vaccines triumph over other viral infections in humans and domestic animals?

Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron

Feline coronavirus-infected domesticated cats found to possess cross-reactive anti-SARS-CoV-2 antibodies

Pocket feature in SARS-CoV-2 spike protein is present in all deadly coronaviruses, study reveals

Ultrapotent IgM antibodies isolated from a pregnant woman with Zika virus show promise as an immunotherapy

Proteomic analysis identifies novel phenotypes associated with COVID-19 severity in circulating immune cells

Approved and developing passive and active immunizations against respiratory syncytial virus in childhood and pregnancy

The biological properties of the SARS-CoV-2 E protein in the context of HIV-1

Kiwira virus: a new bat-borne hantavirus detected in Africa

NIAID awards more than $12 million for the development of antiviral therapies

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News